Sol-Gel completes Phase 3 enrollment follow-up for Gorlin syndrome drug, expects data late November Nov 12Quarterly updatepatidegibSol-Gel Technologies Ltd.
Sol-Gel sets Nov. 17 annual meeting, proposes renaming to Sol-Gel Therapeutics or DermatologyOct 6PublicationSol-Gel Technologies Ltd.
Sol-Gel completes patient follow-up in Gorlin syndrome Phase 3 trialSep 17Clinical readoutpatidegibSol-Gel Technologies Ltd.
Sol-Gel reports Q2 2026 results, SGT-610 Phase 3 readout on track for late NovemberAug 20Quarterly updatepatidegibSol-Gel Technologies Ltd.
Sol-Gel posts terminated Phase 2 patidegib gel trial results; 2 of 47 had serious adverse eventsJul 21Trial updatepatidegibSol-Gel Technologies Ltd.